Prof Hans Gelderblom speaks to ecancer about the phase III MANEUVER trial.

Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive synovial neoplasm driven by overexpression of CSF-1.

Prof Gelderblom says that pimicotinib, a selective oral CSF-1 receptor inhibitor, demonstrated significant clinical benefit in the Phase 3 MANEUVER study.

In this extended analysis with a median follow-up of 62 weeks, patients treated with pimicotinib showed a high and durable objective response rate, ongoing tumour reduction, and meaningful improvements in clinical outcome assessments such as pain, stiffness, mobility, and physical function.

Prof Gelderblom highlights that responses were maintained beyond the initial treatment period, and patients who crossed over from placebo also derived benefit. The safety profile remained consistent and manageable, with no new or unexpected toxicities identified.

He concludes by saying that these findings support pimicotinib as an effective long-term treatment option for eligible patients with TGCT.